SAN DIEGO--(BUSINESS WIRE)--Jan. 7, 2016-- Illumina, Inc. (NASDAQ: ILMN) today announced that it has filed two patent infringement suits in Europe. The patents asserted use cell-free fetal DNA for non-invasive prenatal testing (NIPT).
The first suit was filed against The Doctors Laboratory Ltd, TDL Genetics Ltd, and Ariosa Diagnostics, Inc. in the High Court of Justice, Chancery Division in the United Kingdom. The suit accuses The Doctors Laboratory and TDL Genetics’ use of the Harmony™ NIPT test supplied by Ariosa of infringing European Patent 0 994 963.
The second suit was filed against Centrum Badań Sp z o.o. and Medgenetix Sp z o.o. in the Regional Court in Warsaw, Poland. The suit accuses Centrum and Medgenetix’s use of the Iona® NIPT test supplied by Premaitha Health PLC of infringing European Patent 2 183 693.
Illumina is seeking all available remedies, including damages and injunctive relief.
These new lawsuits follow suits previously filed against Ariosa in the United States and Premaitha in the United Kingdom.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160107006103/en/
Source: Illumina, Inc.
Illumina, Inc.
Investors:
Rebecca Chambers
858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple
858-882-6822
pr@illumina.com
or
David Robertson, Europe, Middle East and Africa
+44 1223 824909
drobertson@illumina.com
